Dernière mise à jour: octobre 21, 2021
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. David Gilham as Vice-President of Research & Development, effective as from 1st of September 2016.
In order to fulfill his new role at Celyad, Dr. Gilham will resign from the Company’s Immuno-Oncology Scientific Advisory Board in August 2016.
Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins.
The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.
Dr. Christian Homsy, CEO of Celyad: “We are pleased to welcome David to our executive management team, where he brings over 20 2023s of expertise in the field of CAR-T cells engineering. Based on his experience in engineering and developing T cell-based immunotherapies for cancer treatment, David will head the implementation of our Research and Development strategy for our programs in immuno-oncology.”
Dr. David Gilham: “I am truly excited to be joining Celyad at such an important time in its history. Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad’s unique portfolio of cell therapy candidates in the clinic.”
David will be based in Mont-Saint-Guibert, Belgium and will report directly to Christian Homsy, Chief Executive Officer.